Her remission means the world to her.
PROTECT IT.
In the post auto-HSCT consolidation treatment of patients with classical
Hodgkin lymphoma (HL) at high risk of relapse or progression, ADCETRIS®
(brentuximab vedotin) significantly increased PFS compared to placebo1
18.8
month median PFS benefit1
ADCETRIS: 42.9 months (95% CI: 30.4, 42.9†)
Placebo: 24.1 months (95% CI: 11.5, NE)
HR=0.57 (95% CI: 0.40, 0.81) P=0.001
NE=Not estimable. †Estimates are unreliable.
STUDY DESIGN: ADCETRIS